Physician profile
Joy A Sandy
NPI 1013382357
$1,087.45
in general payments reported to CMS, 2019-2025
14 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $468 · 2023: $204 · 2024: $76.04 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $604 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $603.86 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $161.20 | 2022-2024 | Airsupra |
| Vertex Pharmaceuticals Incorporated | $124.74 | 2025 | |
| Novo Nordisk INC | $122.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $109.84 | 2022 | |
| Madrigal Pharmaceuticals | $107.19 | 2025 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.96 | 2022 | |
| Amgen INC. | $75.26 | 2023 | Otezla |
| Sumitomo Pharma America, INC. | $72.26 | 2023 | Gemtesa |
| Boston Scientific Corporation | $58.86 | 2025 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $52.60 | 2022 | |
| Nevro Corp. | $34.75 | 2023 | Senza |
| Axsome Therapeutics, INC. | $33.21 | 2025 | Auvelity |
| Abbvie INC. | $21.55 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Sandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.